Plain-English translation of NCT04712851 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that helps your immune system fight abnormal cells in the cervix. Right now, the standard treatment for high-grade cervical precancerous lesions is surgery to remove them. This study wants to see if the medication alone could eliminate these lesions without surgery, and whether it's safe and well-tolerated.
High-grade cervical precancerous lesions often require surgery, which can have complications and may affect fertility or future pregnancies. Researchers want to find out if this medication could treat these lesions effectively and reduce the need for surgery.
You will receive the medication through an IV infusion lasting about 30 minutes, once every 6 weeks for a total of 4 treatments over 24 weeks. Midway through treatment (after the second dose), you may need a small biopsy to check how the lesion is responding. At the end of the 24-week treatment period, you will have a standard removal procedure to evaluate whether the lesion has been eliminated. You will also have blood tests and visits to monitor how well you tolerate the medication.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States